This inventor holds 5 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Musc Foundation for Research Development. Active years: 2014-2022.
Location History:
- Vernon Hills, IL (US) (2014)
- Mount Pleasant, SC (US) (2017)
- Buffalo Grove, IL (US) (2016 - 2022)
Company Filing History:
Years Active: 2014-2022
Title: Semyon Rubinchik: Innovator in Antibody Research
Introduction
Semyon Rubinchik is a notable inventor based in Buffalo Grove, IL (US). He has made significant contributions to the field of antibody research, holding a total of 5 patents. His work focuses on developing innovative methods for producing anti-nucleolin antibodies, which have potential applications in treating various diseases.
Latest Patents
Rubinchik's latest patents include groundbreaking advancements in anti-nucleolin antibodies. The first patent provides anti-nucleolin antibodies, methods of producing these antibodies, and cells that produce them. Additionally, it outlines methods for using these antibodies in the treatment of both malignant and non-malignant diseases. The second patent focuses on human monoclonal antibodies to human nucleolin, detailing methods of production, cells that produce such antibodies, and their use in diagnosing and treating diseases where nucleolin expression plays a role in the disease's pathophysiology.
Career Highlights
Semyon Rubinchik is affiliated with the Musc Foundation for Research Development, where he continues to advance his research in antibody development. His work has the potential to impact the medical field significantly, particularly in the treatment of diseases associated with nucleolin.
Collaborations
Rubinchik collaborates with talented individuals such as Natalie Sutkowski and Daniel Fernandes, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Semyon Rubinchik's contributions to antibody research exemplify the spirit of innovation in the medical field. His patents and ongoing work hold promise for future advancements in disease treatment.